لاتفيا - اللاتفية - Zāļu valsts aģentūra

orion corporation, finland - salmeteroli xinafoas, fluticasoni propionas - inhalācijas pulveris - 50 µg/500 µg/devā

لاتفيا - اللاتفية - Zāļu valsts aģentūra

sandoz d.d., slovenia - salmeterolum, fluticasoni propionas - inhalācijas pulveris, dozēts - 50/500 μg/dose

لاتفيا - اللاتفية - Zāļu valsts aģentūra

elpen pharmaceutical co. inc (sa), greece - salmeterolum, fluticasoni propionas - inhalācijas pulveris, dozēts - 50 mikrogrami/250 mikrogrami/devā

لاتفيا - اللاتفية - Zāļu valsts aģentūra

elpen pharmaceutical co. inc (sa), greece - salmeterolum, fluticasoni propionas - inhalācijas pulveris, dozēts - 50 mikrogrami/500 mikrogrami/devā

لاتفيا - اللاتفية - Zāļu valsts aģentūra

sandoz d.d., slovenia - salmeterolum, fluticasoni propionas - inhalācijas pulveris, dozēts - 50/250 μg/devā

لاتفيا - اللاتفية - Zāļu valsts aģentūra

boehringer ingelheim international gmbh, germany - fenoterola hidrobromīds - aerosols inhalācijām, zem spiediena, šķīdums - 100 mikrogrami/devā

لاتفيا - اللاتفية - Zāļu valsts aģentūra

sanofi-aventis, spain - hioscīna butilbromīds - supozitorijs - 10 mg

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - zāles obstruktīvu elpceļu slimību, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - zāles obstruktīvu elpceļu slimību, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

لاتفيا - اللاتفية - Zāļu valsts aģentūra

chiesi pharmaceuticals gmbh, austria - formoterola fumarāta dihidrāts - aerosols inhalācijām, zem spiediena, šķīdums - 12 μg/izsmidzinājumā